Odonate Therapeutics Can't Beat Investor Suit Over Drug Trial
By Melissa Angell ( August 4, 2021, 10:13 PM EDT) -- Odonate Therapeutics Inc. can't shake a proposed securities class action accusing the pharmaceutical company of misleading investors by concealing information on a trial for a chemotherapy agent in development, after a California federal judge on Wednesday found that Odonate shareholders sufficiently alleged the company misled them....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.